@article{APS9388,
author = {Jun-lan Yu and Tian-tian Chen and Chen Zhou and Fu-lin Lian and Xu-long Tang and Yi Wen and Jing-kang Shen and Ye-chun Xu and Bing Xiong and Nai-xia Zhang},
title = {NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds},
journal = {Acta Pharmacologica Sinica},
volume = {37},
number = {7},
year = {2017},
keywords = {},
abstract = {Aim: Fragment-based lead discovery (FBLD) is a complementary approach in drug research and development. In this study, we established an NMR-based FBLD platform that was used to screen novel scaffolds targeting human bromodomain of BRD4, and investigated the binding interactions between hit compounds and the target protein.
Methods: 1D NMR techniques were primarily used to generate the fragment library and to screen compounds. The inhibitory activity of hits on the first bromodomain of BRD4 [BRD4(I)] was examined using fluorescence anisotropy binding assay. 2D NMR and X-ray crystallography were applied to characterize the binding interactions between hit compounds and the target protein.
Results: An NMR-based fragment library containing 539 compounds was established, which were clustered into 56 groups (8–10 compounds in each group). Eight hits with new scaffolds were found to inhibit BRD4(I). Four out of the 8 hits (compounds 1, 2, 8 and 9) had IC50 values of 100–260 μmol/L, demonstrating their potential for further BRD4-targeted hit-to-lead optimization. Analysis of the binding interactions revealed that compounds 1 and 2 shared a common quinazolin core structure and bound to BRD4(I) in a non-acetylated lysine mimetic mode.
Conclusion: An NMR-based platform for FBLD was established and used in discovery of BRD4-targeted compounds. Four potential hit-to-lead optimization candidates have been found, two of them bound to BRD4(I) in a non-acetylated lysine mimetic mode, being selective BRD4(I) inhibitors.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/9388}
}